Researchers found no significant differences in disease-free survival, overall survival, and recurrence rates between ...

Crovalimab is a novel anti-C5 recycling monoclonal antibody that is self-administered every 4 weeks. Its recent FDA approval ...

Asthma is worsening under the effects of climate change, such as air pollution and pollen production, especially for underserved populations. Climate change is amplifying existing environmental ...

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA ...

High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free ...

Patients with atopic dermatitis, particularly males and those aged 40 to 59 years, have significantly higher rates of impaired mobility. However, the researchers of the present study noted that the ...

Ishwaria Subbiah, MD, of SCRI Oncology Partners, discusses new findings presented at ASCO 2024. This interview will appear in ...

Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers ...

Patients who received long-acting injectable antipsychotics (LAIs) in the hospital but discontinued them early faced a 22% to ...

In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their ...

Early tests show stem cells can be used to spark expression of a miniature version of the dystrophin protein. The combination ...

On this episode of Managed Care Cast, we're talking with the author of a study published in the June 2024 issue of The ...